Ann: Fast Track Access To Potential Japan Investment Incentives, page-46

So, you're not telling the truth again Dolce. I've agreed with you countless times that the cells are safe.
Unfortunately, it's also not true to say that this distinguishes MSB's cells. There have been countless stem cell studies by many companies and institutions. Overwhelmingly, they have been found to be safe - irrespective of the source. Even embryonic stem cells which were feared to possibly cause teratomas, seem not to do so.
As for your paragraph, quoting me:


That the latest trial didn't demonstrate value as a first line therapy, does not diminish it's value as a second line/third line/rescue therapy.

I quite agree... AND following that logic you are yet to demonstrate why final stage 3 efficacy testing makes MSB an all or nothing proposition.

I'm sorry, I simply don't understand the point your making. Are you saying that if MSB have a successful Phase 3 programme, they'll be able to sell product? If you are, then, or course, you are correct, and everyone will be happy. It seems an oddly obvious point to make though - there must be something else I there that I'm not following. You're going to have to help me out.